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Pediatric Oncologists Search for More
Effective Drugs to Treat an ‘Orphan Disease’
by David Galloway

E

wing’s sarcoma is
what is known as an
orphan disease. Drug
companies don’t get
very excited about finding cures
or treatments for diseases that
affect only 200 to 300 new
patients each year.

“It takes millions of dollars to
develop a new drug. If it’s only going

to be useful in 200 patients a year, it’s
not going to really get the payback, and
the stockholders won’t be happy,” said
Eugenie S. Kleinerman, M.D., head of
the Division of Pediatrics at The
University of Texas M. D. Anderson
Cancer Center. The National Institutes
of Health consider an estimated 6,000
diseases affecting about 20 million
people in the United States to be
orphan diseases, meaning that each
disease affects fewer than 200,000
Americans or that there is no reasonable expectation that the costs of
developing drugs for their treatment

could be recovered from the sale of
the drugs.
Meeting both of the above criteria,
the Ewing’s sarcoma family of tumors is
rare indeed. Many oncologists will work
their whole lives without ever seeing
these tumors that invade the bones or
soft tissues. The small, undifferentiated,
round cells with a common chromosomal abnormality are most frequently
seen in the long bones of the arm or leg,
in the flat bones of the ribs or pelvis, or
in the spine; however, they can develop
in any bone, and 10% to 15% of these
(Continued on next page)
Researchers in the Division of Pediatrics
are studying the biology of Ewing’s sarcoma,
a very rare pediatric cancer, in an effort
to find effective treatments among drugs
developed for other diseases. One such
drug is trastuzumab, an antibody directed
against HER2. Here (from the left),
Dr. Zhichao Zhou, a research
investigator in the Division of
Pediatrics, Dr. Eugenie S.
Kleinerman, head of the
division, and graduate research
assistant Geoffrey Kannan
look at a Northern blot of
HER2 expression in Ewing’s
sarcoma cell lines.
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Oncologists Search for Effective Treatments for Ewing’s Sarcoma
(Continued from page 1)
tumors arise outside of bone. Most
patients are 10 to 20 years old and white
or Hispanic (the disease is very uncommon among African Americans).
Patients may present with pain, stiffness,
or tenderness, along with swelling or a
mass in the area of the tumor; weight loss
and fever are also common. Ewing’s
sarcoma is frequently diagnosed after a
pathologic fracture of a bone weakened
by a tumor. The two-year metastasis-free
survival rate for patients with Ewing’s
sarcoma is only about 40% (the five-year
survival rate for patients who do not
have metastatic disease at presentation is
60%), and the disease tends to metastasize
to the lungs, bones, and bone marrow,
often resulting in death very quickly.
The current standard treatment for
Ewing’s sarcoma consists of induction
chemotherapy (vincristine, doxorubicin,
and cyclophosphamide), followed by
surgical resection of the tumor, radiotherapy, or both. Further chemotherapy
is given after local therapy. This combination has not significantly improved
disease-free survival rates, however,
so researchers are looking for other
treatments.
Dr. Kleinerman hopes a drug used to
treat breast cancer also will be effective
against Ewing’s sarcoma. “In the lab, we’ve
shown that one of the proteins that is
overexpressed in breast cancer, HER2,
also is overexpressed in Ewing’s sarcoma.
And we’ve shown that if you downregulate HER2, the Ewing’s cells become
more sensitive to chemotherapy.” That
would mean patients could be treated
with lower doses of chemotherapy—and,
in turn, experience fewer toxic effects—
while still receiving the full benefit
from the chemotherapy treatment. Dr.
Kleinerman plans to test this hypothesis
using trastuzumab (Herceptin), a recombinant humanized mouse monoclonal
antibody directed against HER2, in a
mouse model of Ewing’s sarcoma. If
trastuzumab proves effective in vivo,
clinical trials could be planned.
“The advantage is that this is a drug
that’s already commercially available,”
Dr. Kleinerman said. “Nobody has to
develop it. It’s in the clinic for breast
cancer, so the fact that we have a rare
disease doesn’t matter. And that’s really
2
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“There needs to be
funding for sarcoma
research just like breast
cancer research,
particularly because
we’ve made no major
advances in 20 years
in this disease.”
– Eugenie S. Kleinerman, M.D.,
division head, Division of Pediatrics

where I’ve turned to. I think the best
approach for these rare diseases is to try
to understand the biology and see if
there are any other tumors where agents
have been developed that we can use
rather than developing our own.”
Dr. Kleinerman also is enrolling
newly diagnosed Ewing’s sarcoma
patients in a phase II trial of a liposomeencapsulated lipophilic disaccharide
tripeptide derivative of muramyl dipeptide (ImmTher) that stimulates white
blood cells to kill tumor cells. “We had
some success with a sister compound
called MTP [muramyl tripeptide phosphatidylethanolamine] in osteosarcoma,
and because Ewing’s sarcoma spreads to
the lungs like osteosarcoma, we thought
maybe this new drug would have some
value,” Dr. Kleinerman said. Unfortunately, the company that made ImmTher
has ceased its production; however, all
the remaining stockpile of the drug was
shipped to M. D. Anderson. “So, we
have the world’s supply of ImmTher,”
Dr. Kleinerman said. “There is no more.”
Cynthia E. Herzog, M.D., an associate
professor of pediatrics at M. D. Anderson, explained that ImmTher stimulates
macrophages. “The principle behind this
is that if you treat patients until they
have only microscopic disease, you could
then give them an agent that stimulates
the immune system and hopefully have
the immune system take care of the
microscopic disease. For Ewing’s, one of
the prime sites of metastasis is the lungs,
which is an area that is rich in macrophages that are stimulated by this agent,
and so our hope is that it will have some

activity and help prevent recurrences.
We’re still accumulating patients, so
it will be a little while before we have
an answer to this question.”
The poor prognosis for patients
who have had a recurrence of Ewing’s
sarcoma is of particular concern to
researchers. Dr. Herzog is opening
another phase II trial for such patients
to test a topoisomerase I inhibitor
known as exatecan mesylate (DX8951f). “It’s a third-generation drug,
and the two previous generations—
topotecan and irinotecan—have both
shown some activity. This one [DX8951f] seems to have activity even
in tumors that are resistant to its
predecessors,” Dr. Herzog said.
Unfortunately, Dr. Kleinerman said,
very little current research is focusing
on Ewing’s sarcoma. A fact of life in the
world of research is that laboratories need
funding. Dr. Kleinerman said there are
“large pots of money” available for the
study of breast cancer, prostate cancer,
lung cancer, and colon cancer, so researchers often switch their focus to areas
where they can get the funding. “We’ve
seen a great switch to breast cancer
research over the past 10 years, which is
good, because there have been a lot of
breakthroughs,” Dr. Kleinerman said.
“But at the same time, nobody’s interested
in Ewing’s sarcoma, because there are no
special funding opportunities.”
Dr. Kleinerman believes research
into orphan diseases calls for special
incentives. “I think that somebody has
to make the argument that there needs
to be funding for sarcoma research just
like breast cancer research, particularly
because we’ve made no major advances
in 20 years in this disease,” she said.
“I think it’s important that perhaps
the federal government get involved
in making it more attractive for drug
companies to develop new therapies
for these rare diseases by offering patent
benefits or expedited approval. But it’s
very clear to me that if you just leave it
to the free market, we’re not going to
see any improvement.” ●
FOR MORE INFORMATION, contact
Dr. Kleinerman at (713) 792-8110
or Dr. Herzog at (713) 745-0157.

Collaborative Studies
Lead to Better Survival
Rates in Young Patients
with Rhabdomyosarcoma
by Ann Sutton

R.

Beverly Raney, Jr.,
M.D., has treated
thousands of
patients in the almost
30 years that he has been practicing medicine. Some of his patients he remembers better than
others; one he will never forget.
Several years ago, Dr. Raney treated
a young boy with rhabdomyosarcoma
who had a tumor in his thigh. At that
time—a time when more than half of
patients with rhabdomyosarcoma died of
the disease—the standard treatment for
tumors of the extremities was amputation. The boy’s leg was removed, but the
treatment team later found lymph node
involvement higher up, in the pelvis.
“What is the point of taking off a
leg if you’ve already got disease above
it?” asked Dr. Raney, a professor in the
Division of Pediatrics at The University
of Texas M. D. Anderson Cancer
Center. “A year later, he had lung
disease and died. But he could have

lived that year with both of his legs
rather than as an unhappy four-year-old
amputee.”
That experience led Dr. Raney to
study ways to improve the outcomes of
patients with rhabdomyosarcoma. He
became a member of the Intergroup
Rhabdomyosarcoma Study, now called
the Soft Tissue Sarcoma Committee
(STSC), a collaboration between
members of the Children’s Cancer
Group and the Pediatric Oncology
Group (now called the Children’s
Oncology Group) that investigates
rhabdomyosarcoma and undifferentiated
sarcoma in patients less than 21 years
old. Primarily because of the research
conducted by the STSC, survival
outcomes have substantially improved
for children with this rare disease—the
overall five-year survival rate has risen
from about 55% in the mid-1970s to
70% today, and patients with localized
disease now have an 85% survival rate.
The STSC has completed several
studies—studies I through IV, plus
additional pilot through IV studies for
patients with advanced disease. Each
study is a separate protocol that builds
on the findings of the previous studies.

“The big issues for
children with this
disease are to try to
figure out how to
preserve life and
also preserve
function.”
– R. Beverly Raney, Jr., M.D.,
professor, Division of Pediatrics

Study V began recruiting patients in
1997 and, according to Dr. Raney,
should be completed within the next
three years. Study VI is already being
planned. Recent emphasis, such as in
study V, has been on shrinking the
tumor with chemotherapy or radiation
therapy before surgery so that it can
be removed with the least damage to
organ function or patient appearance.
“We try to do major surgery at the
beginning, provided it is safe and won’t
impair function significantly. But if it is
not considered safe or would lead to a
functional or cosmetic result that’s not
appropriate, we try to shrink the tumor
first, nonsurgically, and then consider
removing the residual tumor, if that’s
feasible, later,” said Dr. Raney.
In studies I-III, patients were
grouped by the extent of both their
disease and the initial surgical resection.
However, over the years, the STSC
developed a new staging system for
rhabdomyosarcoma that was not
dependent on the surgeon’s decisions
about resection or on pathologic
assessments of the tumor. The new
system is based on the tumor-nodemetastasis (TNM) system developed
by the American Joint Committee on
Cancer and categorizes patients by site
of the primary tumor, tumor size, and
lymph node involvement or metastasis.
Based on the results of STSC studies,
the current standard of care for most
patients with rhabdomyosarcoma is a
combination of chemotherapy (vincristine,
dactinomycin, and cyclophosphamide),
surgical excision, and radiation therapy.
“The big issues for children with
this disease are to try to figure out how
to preserve life and also preserve
function. A lot of these tumors arise
above the clavicle, in the head and
neck—visible parts of the body. You
cannot do major surgery on a child’s
face just because it’s a good idea
to take all the tumor out. It is a bad
idea to leave them with a face that is
very deformed,” said Dr. Raney.
One of the techniques used most
recently in patients with rhabdomyosarcoma is sentinel lymph node mapping.
“In past years, people thought that
rhabdomyosarcoma rarely spread to lymph
nodes. That was really because no one was
(Continued on page 4)
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Studies Lead to Better Survival Rates in Patients with Rhabdomyosarcoma
(Continued from page 3)

doing a biopsy on them. After doing
sentinel lymph node mapping for melanoma, I thought that we could use the
same technique for rhabdomyosarcoma
of the extremities and chest wall. So we
started using the lymphoscintigraphy and
blue dye just as in melanoma and found
out that it works well. Instead of only
12% of rhabdomyosarcoma patients
having positive nodes, it turns out that
50% have positive nodes and thus require
radiation therapy to the regional nodes,”
said Richard Andrassy, M.D., a pediatric
surgeon, chair of the Department of
Surgery at The University of Texas
Health Science Center at Houston
Medical School, and member of the
STSC.
Second-look surgery, in which a
surgeon examines the disease site after
chemotherapy to see if any cancer
remains, has been another successful
technique in patients with rhabdomyosarcoma. Sometimes less invasive
methods, such as computed tomography,
cannot detect all remaining cancer.
“Second-look surgery is particularly
helpful in areas that are hard to see,
such as the retroperitoneum and
abdomen,” said Dr. Andrassy.
Rhabdomyosarcoma is cancer of
striated muscle that arises from embryonic mesenchyme. Cells resemble
rhabdomyoblasts (fetal premuscle cells).
Approximately 350 patients 0 to 20
years old are diagnosed with the disease
each year in the United States, and

“We have come a
long way toward
understanding the
disease and improving
the outcome of
multidisciplinary care
for patients with
rhabdomyosarcoma.”
– R. Beverly Raney, Jr., M.D.,
professor, Division of Pediatrics

4
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Dr. Raney estimates that about 80%
of those patients enter an STSC trial.
Overall, two thirds of children with
rhabdomyosarcoma will survive with
proper treatment.
Embryonal rhabdomyosarcoma is
the most common type (60% to 70%
of cases), occurring mostly in the head
and neck and genitourinary tract,
usually in infants and young children.
Botryoid rhabdomyosarcoma is a
subtype of embryonal rhabdomyosarcoma that usually occurs in infants and
is most commonly found in the vagina
and bladder. Spindle cell rhabdomyosarcoma, another embryonal disease,
accounts for approximately 10% of all
rhabdomyosarcoma cases. It is usually
found in the paratesticular area. Approximately 20% of rhabdomyosarcoma
cases are of the alveolar type, which
occurs mostly in the large muscles of
the trunk, arms, and legs and is most
common in older children and adolescents. Alveolar rhabdomyosarcoma is
the most aggressive and dangerous type.
The remaining subtype of rhabdomyosarcoma is pleomorphic, which occurs
mainly in adults 30 to 50 years old.
“It’s a very complex disorder that
can occur anywhere in the body. The
only place it doesn’t originate is within
a bone. But it can spread to bones, so we
have to think about bones when looking
at this disease overall,” said Dr. Raney.
Environmental risk factors for rhabdomyosarcoma may include parental
use of marijuana or cocaine, intrauterine
x-ray exposure, and exposure to alkylating
agents. Genetic factors include a family
history of Li-Fraumeni syndrome or a
personal history of Beckwith-Wiedemann
syndrome or neurofibromatosis. Rhabdomyosarcoma has also been associated
with p53 mutations, chromosome 13
translocation, Rubinstein-Taybi syndrome, and Gorlin’s syndrome.
Primary tumors located in the
nonparameningeal head and neck,
paratestis, vagina, orbit, and biliary
tract have the most favorable outcome.
In fact, the cure rate for orbital rhabdomyosarcoma is almost 100%.
“Those patients have a very good
outlook, probably because you can see

a 3- or 4-mm tumor if it is sticking out
from under an eyelid,” said Dr. Raney.
The standard treatment for orbital
rhabdomyosarcoma in the United
States is chemotherapy and radiation
therapy. Physicians in Europe, however,
are wary of administering radiation
therapy to the eye because it can
cause cataracts.
The STSC is currently evaluating
two new agents, topotecan and
irinotecan, for the treatment of rhabdomyosarcoma, particularly the alveolar
subtype. “This is an ongoing major area
of interest because the survival rate for
most of these patients is 50% to 60%,”
said Dr. Raney.
For patients whose tumors have
failed to respond or have recurred after
initial therapy, researchers are studying
combinations of active drugs that have
not been previously administered. Two
of these new agents, which are being
evaluated for the treatment of patients
with recurrent rhabdomyosarcoma, are
available at only a few institutions in
the United States, including M. D.
Anderson. One of them is lipovincristine, a liposomal formulation of
vincristine that is released more slowly
in the body and can be given less
frequently. Patients who have been
treated with regular vincristine can
still have tumor shrinkage after therapy
with lipovincristine. The other drug is
called exatecan, which is a member of a
relatively new class of topoisomerase I
inhibitors that includes topotecan. Each
of these new drugs can be given in the
outpatient setting, which is usually more
convenient and less expensive than
inpatient treatment.
“We have come a long way toward
understanding the disease and improving the outcome of multidisciplinary
care for patients with rhabdomyosarcoma,” said Dr. Raney. “The search for
new methods of cure and new active
drugs, together with improvements in
surgery, radiation therapy, and supportive care, continues here in the Division
of Pediatrics and beyond.” ●
FOR MORE INFORMATION, contact
Dr. Raney at (713) 792-6624.

Protecting the Heart and Gastrointestinal
Tract from Treatment-Associated Damage
Is an Important Element of Cancer Care
by Katie Prout Matias

P

atients who successfully undergo treatment for cancer
could find themselves
battling a new illness later
on. Because of the inherent
toxicity of chemotherapy and
problems associated with
radiation therapy, the possibility of organ damage in
patients with cancer is a
very real concern.

Owing to their locations and functions, the heart and the gastrointestinal
(GI) tract can be adversely affected by
treatments for many kinds of cancer.
For example, damage to the heart is
most commonly associated with chemotherapy for breast cancer and radiation
therapy for lung cancers. The GI tract
can be affected by treatments for head
and neck, cervical, and prostate tumors,
as well as by primary cancers of the
esophagus, colon, stomach, and
pancreas, among others.
Treatment-related cardiac damage
Chemotherapy and radiation therapy
can damage the heart directly. Myocardial
depression is associated with some forms
of chemotherapy, whereas other agents
can cause ischemia, hypotension, and
rhythm disturbances. Radiation is
associated with pericarditis and, rarely,
ischemic heart disease. Much of the
cardiac damage seen following cancer
treatment is mild, but it is nevertheless
present and can exacerbate subsequent
damage associated with infections,
excessive alcohol ingestion, or pregnancy.
“That is the concept of sequential
stress, which was first described here at
M. D. Anderson. The first stress is the
chemotherapy-associated damage, and
the second stress is the additional

damage associated with
a variety of insults. All of the
damage is additive and results in
cardiomyopathy. Because of the
subclinical damage caused by
chemotherapy, you get an
exaggerated reaction later on
that can be very, very troublesome and in some instances
can cause heart failure and even
death,” said Michael S. Ewer,
M.D., M.P.H., J.D., a professor
in the Department of Cardiology at The University of Texas
M. D. Anderson Cancer Center.
Anthracycline antibiotics,
such as doxorubicin and
daunorubicin, present the most
notorious threat to the heart.
The exact mechanism behind
the cardiotoxicity of anthracyclines is still being researched,
but modalities have been
developed that lessen treatment-associated damage.
“Since cardiac damage probably
starts from the very first dose, it
is prudent to think about protection
at the beginning and not after you
begin to recognize that some
damage might have occurred,”
said Dr. Ewer.
Preventing and treating
cardiotoxic effects
One way to prevent or reduce the
toxic effects of a drug is to limit the
total dose given; however, giving a
lower dose may make the drug less
effective in some patients. Researchers
at M. D. Anderson developed a technique whereby some forms of cardiotoxic chemotherapy are administered
as a continuous infusion over 48 to
96 hours. This method reduces cardiotoxicity without significantly lowering
the drug’s efficacy.
In one of several studies comparing
bolus regimens with continuous infusion,
82 patients with soft tissue carcinomas
were randomly assigned to receive

Protecting the heart from damage due to
chemotherapy should be a priority from the
very beginning of treatment, according to
Dr. Michael S. Ewer, a professor in
the Department of Cardiology.
doxorubicin as a bolus or as a 72-hour
continuous infusion. Cardiotoxic effects
were seen in 61% of the patients receiving the bolus regimen at a median
cumulative dose of 420 mg/m2, compared
with only 42% of those receiving the
continuous infusion at a higher median
cumulative dose of 540 mg/m2.
“It seems to be that the peak plasma
level is more likely to cause cardiac
damage, whereas the total amount given
leads to tumor control,” said Dr. Ewer. “So
if you give the same amount over a longer
period of time, you have a lower peak in
the plasma level, and that seems to be
associated with less cardiac damage.”
Oncologists are also finding promise
in the administration of protective
(Continued on page 6)
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Preventing and Controlling Damage to the Heart and GI Tract
(Continued from page 5)

agents such as iron chelators and in
the use of anthracycline analogues or
anthracyclines that are less cardiotoxic than is doxorubicin. The
latest research, however, focuses on
the use of liposomal formulations of
standard drugs. “The liposomal
preparations encapsulate the active
drug and release it at the tumor
location,” said Dr. Ewer. Studies have
shown that liposomal formulations
cause fewer cardiotoxic effects than
do unencapsulated drugs and demonstrate excellent antitumor efficacy.
Other encouraging news comes
from a study recently conducted at
M. D. Anderson, which found that
standard therapies for heart failure
such as ACE-inhibitors, betablockers, diuretics, and inotropic
agents control some of the manifestations of chemotherapy-induced
heart failure.
Effects of radiation therapy
on the GI tract
Like the heart, the gastrointestinal tract is susceptible to long-term,
treatment-associated damage, especially
from radiation therapy. In the narrow
tubal structures of the GI system,
stricturing is perhaps the most common
problem. Stricturing occurs as the
inflamed organ begins to heal; the
scar contracts, narrowing the passageway.
In patients receiving radiation
therapy for chest and head and neck
cancers, the esophagus is particularly
susceptible to stricturing. “The esophagus can get in the way as an innocent
bystander,” said Patrick Lynch, M.D.,
J.D., associate professor in the Department of Gastrointestinal Medicine
and Nutrition at M. D. Anderson.
Similarly, radiation therapy for
prostate and cervical cancers can cause
damage to the lower colon and rectum.
“Unlike the esophagus, which mainly
has stricturing as a problem, in the
rectum, the problem is usually bleeding,” said Dr. Lynch. “Patients develop
vascular ectasias, dilated blood vessels
in the rectum that are very fragile
and bleed very easily.”
6
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“Although most of our
efforts are oriented
toward improving
outcomes—reducing
cancer death and local
recurrence—a lot of our
focus is quality of life.”
– Patrick Lynch, M.D., J.D.,
associate professor, Department of
Gastrointestinal Medicine and Nutrition

Treating strictures and
preventing radiation damage
Dr. Lynch said that in cases of
stricturing, an endoscope is used to
dilate the constricted tube; argon
plasma coagulation and cauterization
are effective in treating bleeding. In
more simple cases of inflammation,
topical steroids and acid-blocking
medications work.
Like treatment-related cardiomyopathies that develop years down the road,

GI problems can occur or recur long
after the treatments are over. “Strictures can be chronic problems that
keep bringing folks back over and
over,” said Dr. Lynch. “Dilation is
something that has to be done over
and over as an alternative to surgery.”
Whereas researchers have
already developed several promising
techniques to prevent chemotherapy-related heart damage,
preventing radiation damage to
the GI system has proven more
difficult. One technique involves
using a “belly board” to move parts
of the abdomen away from the
field of radiation. The board has
a hole cut out of it that allows
the abdomen to fall through it
when the patient lies prone.
“One of the biggest problems is
stricturing and damage to the
small bowel,” said Dr. Lynch.
“The board uses gravity measures
to get the small intestine out of
the way of the radiation.”
Another way to protect the
GI system is to give chemoradiation
treatments before surgery instead of
after, because once the operation is
performed, the organ is already susceptible to scarring and is more likely to
stricture when given chemoradiation.
According to Dr. Lynch, most of the
physicians and researchers at M. D.
Anderson believe that giving radiation
treatment before surgery improves the
outcome and reduces many of the
toxic effects.
“Although most of our efforts are
oriented toward improving outcomes—
reducing cancer death and local recurrence—a lot of our focus is quality
of life, reducing GI toxicities and
complications,” said Dr. Lynch.
While cancer treatments continue
to be inherently toxic, finding ways
to prevent or heal damage, and thus
improve the quality of life for survivors
of cancer, remains an important aspect
of cancer care. ●
FOR MORE INFORMATION, contact
Dr. Ewer at (713) 745-2216 or
Dr. Lynch at (713) 794-5073.
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Conquering the Pain of Cancer

P

ain is one way the
body has of telling
us something is
happening inside us.
Cancer pain can be caused by
the growth of a tumor and by
the side effects of treatments
such as chemotherapy.

However, unrelieved pain does not
have to be accepted as a normal part
of having cancer, according to the
American Cancer Society. Pain may
worsen feelings of weakness, and it
may interfere with your enjoyment
of life and your ability to sleep and eat.
It may even interfere with healing.
What should I do if I have pain?
Describe your pain to your healthcare provider. There is no other way for
your health-care provider to know how
much or what kind of pain you have.
Tell your doctors and nurses where you
feel pain, and point to the place on your
body or on a picture of the body. Describe what kind of sensation it is (sharp
or dull, steady or pulsating, shooting or
in one spot, burning, fullness, numbness,
tingling, tightness, etc.); if it varies with
the time of day, with a particular movement, or with general activity; and any
possible “triggers” that start the pain.
Talk to your doctor about your
concerns about pain medicines.
Many patients are uncomfortable
asking for pain medication or for a
higher dose because they fear becoming
a drug addict. If you take opioid pain
medication, your body will most likely
become used to the medication (develop a tolerance), and you will need a
higher dose to feel the same relief that a
lower dose used to give you. Tolerance
to pain medication and physical dependence are different from psychological
dependence or drug abuse. Some
patients are concerned about the side
effects that opioids can cause, such as
nausea, constipation, and difficulty
thinking clearly. If side effects occur, a

pain medication. Some patients have
found comfort through acupuncture
and massage, which are available in
many communities. Self-hypnosis,
guided imagery, and biofeedback are
pain management techniques that
What is breakthrough pain?
patients can learn from trained theraMany people experience pain once
pists through individual or group
in a while even after they have begun
instruction. M. D. Anderson Cancer
taking pain medicine regularly. This
Center’s Place…of Wellness offers
intermittent pain is called “breakclasses in these and other
through” pain because it “breaks
techniques. You do not have to
through” the effects of the
be a patient at M. D. Anderson
regular pain medication. If you
Take As
Needed
to take these classes. If you are
For
experience this kind of pain, it
not able to come to M. D.
does not mean that the regular
Pain
Anderson, look in your commupain medicine is not working.
Relie
f
nity for spas and health clubs
Breakthrough pain does not
that offer instruction in similar
usually last very long but can be
mind-body techniques.
very intense. Certain fast-acting
pain medications and techniques
Ask to see a pain
such as guided imagery and distraction
management specialist.
can be very helpful in treating this
Just as some doctors specialize in the
kind of pain.
treatment of cancer or in the treatment
of a certain kind of cancer, other doctors
Keep your doctor updated about
specialize in the treatment of pain. You
changes in your pain and in the
can see a pain specialist on your own or
medication’s ability to control it.
ask your doctor to consult with a pain
Because pain is one of the body’s
specialist if you feel you would like more
ways of telling us what is happening,
options to help treat your pain than the
pain can help your doctor understand
ones your doctor offers you. These
how your cancer is responding to
options may include other medications
treatment and how your whole body is
or certain anesthetic injections or
responding to the cancer and to treatsurgical procedures for pain.
ment. Also, the sooner your pain is
treated, the better your chances of
Above all, don’t suffer in silence.
getting relief. If you wait, the pain
Tell
a doctor or nurse about any pain
medication will have to “catch up”
that
you are having, and let them know
with your pain, possibly requiring
when
your pain medications aren’t
more than one dose of pain medication
working.
Remember, treatments for
before you feel relief. You may have
pain
only
work when they are used. ●
to wait a couple of hours before the
second dose, and that is a long time
to be in pain! Different medications
For more information, contact
may be tried until your doctor finds
your physician or contact the
the one or ones that work best for
M. D. Anderson Information Line:
you at a particular time.
change in the dosage or in the particular
medication can help. Your doctor often
will prescribe medications just for the
side effects.

Many ways to treat pain
are available.
In addition to the different kinds of
pain medications, some patients have
found relief by using complementary
techniques to ease pain. These techniques can be used at the same time as

392-1611 within
✆ the(800)
United States, or
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DiaLog
Recognizing and Treating Cognitive Dysfunctions
in Survivors of Childhood Cancers
Donna R. Copeland, Ph.D.
Professor, Department of Pediatrics
Even though most
children with cancer
will survive, they are
at increased risk for
long-term cognitive
sequelae as a consequence of central
nervous system
(CNS) involvement
and treatment. Brain
functions most likely affected include
attention/concentration, intelligence,
memory, psychomotor abilities, and academic skills. Deficits can be progressive,
and as cancer survivors enter adulthood,
unemployment becomes common.
CNS cancers are treated with cranial
radiation therapy (CRT) or chemotherapy.
The prophylactic treatment of CNS metastases
in patients with leukemia or lymphoma
involves a much lower dose than that used
to treat primary CNS tumors. Nevertheless,
neuropsychological studies have confirmed
that these lower doses of CRT can still result
in significant cognitive impairment. The
effects of chemotherapy administered to
the CNS may be much less than those
associated with CRT, but academic declines
and attention deficits are still observed.
Evidence exists of an association between
attentional abnormalities and structural
abnormalities in the brain following CNS
treatment. In studies of childhood leukemia
survivors, neuropsychological tests and
imaging scans demonstrated that
1) problems in reaction time, shifting
8
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attention, and sustained attention were
common; 2) children with more severe CNS
lesions (i.e., intracerebral calcifications)
had the greatest deficits in these tasks; and
3) problems with attention were significantly
correlated with problems in higher-order
cognitive processes such as memory and
learning. More recently, similar findings from
a much larger sample of leukemia survivors
showed low scores on Freedom from Distractibility Factor (Wechsler scales), arithmetic
computation, and mental concentration
tests—all of which correlated with abnormalities found in imaging studies.
So the evidence is clear that survivors
of childhood leukemia and intracranial
tumors are at risk for learning difficulties.
We can help these patients, however.
Physicians who follow up on survivors of
childhood cancers can make a point of
asking them how they are faring in school
or work. If difficulties are reported, I
recommend a referral to a neuropsychologist who is familiar with the effects of
childhood cancer and its treatment. The
neuropsychologist can evaluate the patient
to ascertain the cognitive functions involved and take appropriate action, which
is likely to entail a consultation with the
young person’s school. Ideally, a cognitive
remediation program will be available.
These programs are designed to teach the
cancer survivor ways to compensate for
deficits. Also, stimulants are sometimes
effective in ameliorating the attentional
deficits that occur as a result of CNS
disease and treatment, and tutoring,
special education classes, or both can
help students with school subjects.
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